Article
Immunology
Biao Gao, Yafei Wang, Chonghui Li, Shichun Lu
Summary: This study constructed a novel prognostic signature related to estrogen-related genes in HCC. The signature was found to be an independent risk factor for predicting patient prognosis and immunotherapy response. It was positively correlated with various immunotherapy response-related factors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Mikiya Tsunoda, Hiroyasu Aoki, Haruka Shimizu, Shigeyuki Shichino, Kouji Matsushima, Satoshi Ueha
Summary: Temporal analysis of T cell receptor (TCR) repertoire is important for monitoring changes in antigen-specific T cells in cancer patients. However, lack of experimental models for temporal analysis within a homogeneous population limits understanding of the relationship between TCR repertoire changes and antitumor responses. Bilateral tumor model showed highly similar T-cell clones in bilateral tumors and different patterns in draining lymph nodes, suggesting independent induction of tumor-reactive T cell clones in each lymph node.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Xinjun Lu, Shanshan Deng, Jiejie Xu, Benjamin L. Green, Honghua Zhang, Guofei Cui, Yi Zhou, Yi Zhang, Hongwei Xu, Fapeng Zhang, Rui Mao, Sheng Zhong, Thorsten Cramer, Matthias Evert, Diego F. Calvisi, Yukai He, Chao Liu, Xin Chen
Summary: Combining AFP vaccine with immune checkpoint inhibitors may be effective for treating AFP (+) HCC patients who do not respond to first-line treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Pharmacology & Pharmacy
Yuanyuan Liu, Shuai Chen, Simon Liu, Kevin L. Wallace, Marietta Zille, Jiewen Zhang, Jian Wang, Chao Jiang
Summary: Stroke is a severe and life-threatening disease that requires more research on new treatment strategies. Infiltrated T lymphocytes play a crucial role in post-stroke inflammation and have conflicting roles as therapeutic targets. Understanding the mechanisms of the adaptive immune response associated with T lymphocytes is essential for developing effective treatments.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Oncology
Philippe Rochigneux, Brice Chanez, Bernadette De Rauglaudre, Emmanuel Mitry, Christian Chabannon, Marine Gilabert
Summary: The mortality of hepatocellular carcinoma (HCC) is rapidly increasing worldwide, and immunotherapy involving engineered T cells has shown promising results in clinical trials for combating liver cancer.
Article
Gastroenterology & Hepatology
Yipeng Ma, Jiayu Ou, Tong Lin, Lei Chen, Junhui Chen, Mingjun Wang
Summary: This study presents an HBV-specific TCR identification method that does not require the TCR singularization process, using ranking-based and alpha-beta chain mixture-based strategies. These strategies are effective for identifying HBV-specific TCRs and may be used for treating HBV-related HCC.
HEPATOLOGY COMMUNICATIONS
(2021)
Review
Oncology
Harriet Roddy, Tim Meyer, Claire Roddie
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally. The current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers limited clinical benefit. Cellular immune therapies, such as CAR-T and TCR-T, are being explored as potential treatment options for HCC. Advanced engineering solutions are also being investigated to enhance the therapeutic approach.
Review
Immunology
Zhuoyan Liu, Xuan Liu, Jiaxin Liang, Yixin Liu, Xiaorui Hou, Meichuan Zhang, Yongyin Li, Xiaotao Jiang
Summary: Hepatocellular carcinoma (HCC) is a common primary liver cancer with poor prognosis. Cancer immunotherapy has provided new opportunities for treating HCC, but faces challenges such as various etiologies and immune evasion.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Meagan R. Rollins, Jackson F. Raynor, Ebony A. Miller, Jonah Z. Butler, Ellen J. Spartz, Walker S. Lahr, Yun You, Adam L. Burrack, Branden S. Moriarity, Beau R. Webber, Ingunn M. Stromnes
Summary: TCR transgenic mice are a valuable tool for studying antigen-specific immune responses. The TRex methodology, which integrates TCRs specific to the self/tumor antigen mesothelin (Msln) into the Trac locus, is shown to improve the functional sensitivity of lower affinity TCRs and confer resistance to T cell functional loss. By comparing TCRs with the same specificity but different affinity, the Trac-targeted TCRs are shown to have increased avidity over transgenic TCRs while preserving physiological T cell development. Overall, the TRex methodology is an advanced tool for studying physiological antigen-specific T cell behavior.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Mohamed S. Hussein, Qi Li, Rui Mao, Yibing Peng, Yukai He
Summary: Overexpression of c-Jun in TCR-engineered T cells can enhance their expansion, function, and persistence in hepatocellular carcinoma, leading to improved anti-tumor efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Dandan Li, Chao Chen, Jingjing Li, Jianhui Yue, Ya Ding, Hailun Wang, Zhaoduan Liang, Le Zhang, Si Qiu, Geng Liu, Yan Gao, Ying Huang, Dongli Li, Rong Zhang, Wei Liu, Xizhi Wen, Bo Li, Xiaoshi Zhang, Xi Zhang, Rui-Hua Xu
Summary: This study reports the preliminary results of a personalized adoptive T cell therapy for locally advanced or metastatic solid tumors refractory. The results suggest that Neo-T therapy without lymphodepletion could be a safe and promising regimen for advanced solid tumors.
NATURE COMMUNICATIONS
(2023)
Review
Immunology
Yifan Xu, Jin Jiang, Yutong Wang, Wei Wang, Haokun Li, Wenyu Lai, Zhipeng Zhou, Wei Zhu, Zheng Xiang, Zhiming Wang, Zhe Zhu, Lingfeng Yu, Xiaolan Huang, Hua Zheng, Sha Wu
Summary: Gynecologic malignancies are leading causes of death among women worldwide, and adoptive T cell therapy using engineered T cells has shown promising efficacy in treating tumors. Ongoing research is driving the application of this therapy in the treatment of gynecologic malignancies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Chang Liu, Hong Liu, Moumita Dasgupta, Lance M. Hellman, Xiaogang Zhang, Kai Qu, Hui Xue, Yun Wang, Fenling Fan, Qi Chang, Duo Yu, Linhu Ge, Yu Zhang, Ziyou Cui, Pengbo Zhang, Bradley Heller, Hongbing Zhang, Bingyin Shi, Brian M. Baker, Cheng Liu
Summary: This article describes a novel TCRm-based T cell therapy that shows specificity and safety for hepatocellular carcinoma (HCC). The therapy exhibits potent activity against AFP-positive cancer cell lines in both in vitro and in vivo models without affecting AFP-negative cells. In a human safety assessment, no significant adverse events were observed, and evidence of efficacy was seen. Remarkably, one metastatic HCC patient achieved complete remission after nine months and qualified for a liver transplant.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Fei Lu, Xiao-Jing-Nan Ma, Wei-Lin Jin, Yang Luo, Xun Li
Summary: Immunotherapy is crucial in the comprehensive treatment of HCC, but faces challenges in immune cell specificity and responsiveness. TCR-T cell therapy is considered one of the most promising immune cell therapies for solid tumors, with ongoing research into its application in HCC treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Junwei Liu, Saisi Qu, Tongtong Zhang, Yufei Gao, Hongyu Shi, Kaichen Song, Wei Chen, Weiwei Yin
Summary: The tumor microenvironment (TME) is a complex ecosystem involving various cell types, and understanding the interactions between cancer cells and immune cells within the TME is crucial for cancer biology and tumor immunology. The rapid development of single-cell techniques provides powerful tools to profile the omics status of the TME at single-cell resolution, shedding light on cancer pathogenic mechanisms and dysfunctions of tumor immunity. Advanced techniques that can characterize multi-omics and spatial information at the single-cell level are also being developed to reveal disease-specific cell populations comprehensively and improve clinical diagnosis and prognosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Sha Wu, Wei Zhu, Yibing Peng, Lan Wang, Yuan Hong, Lei Huang, Dayong Dong, Junping Xie, Todd Merchen, Edward Kruse, Zong Sheng Guo, David Bartlett, Ning Fu, Yukai He
CANCER IMMUNOLOGY RESEARCH
(2017)
Article
Gastroenterology & Hepatology
Wei Zhu, Yibing Peng, Lan Wang, Yuan Hong, Xiaotao Jiang, Qi Li, Heping Liu, Lei Huang, Juan Wu, Esteban Celis, Todd Merchen, Edward Kruse, Yukai He
Article
Gastroenterology & Hepatology
Yuan Hong, Yibing Peng, Z. Sheng Guo, Jose Guevara-Patino, Junfeng Pang, Lisa H. Butterfield, Nahid F. Mivechi, David H. Munn, David L. Bartlett, Yukai He
Review
Immunology
Yukai He, Yuan Hong, Gerald J. Mizejewski
Article
Immunology
Yanjun Liu, Yibing Peng, Michael Mi, Jose Guevara-Patino, David H. Munn, Ning Fu, Yukai He
JOURNAL OF IMMUNOLOGY
(2009)
Article
Immunology
Qifeng Zhou, Haiyan Xiao, Yanjun Liu, Yibing Peng, Yuan Hong, Hideo Yagita, Phillip Chandler, David H. Munn, Andrew Mellor, Ning Fu, Yukai He
JOURNAL OF IMMUNOLOGY
(2010)
Article
Immunology
Haiyan Xiao, Yibing Peng, Yuan Hong, Yanjun Liu, Z. Sheng Guo, David L. Bartlett, Ning Fu, Yukai He
JOURNAL OF IMMUNOLOGY
(2011)
Article
Immunology
Yuan Hong, Yibing Peng, Michael Mi, Haiyan Xiao, David H. Munn, Gui-qiang Wang, Yukai He
Review
Biochemistry & Molecular Biology
Leidy D. Caraballo Galva, Lun Cai, Yanxia Shao, Yukai He
JOURNAL OF GENETICS AND GENOMICS
(2020)
Review
Biochemistry & Molecular Biology
Rui Mao, Mohamed S. Hussein, Yukai He
Summary: This article reviews the factors that affect the activation, effector function, in vivo persistence, and antitumor effects of chimeric antigen receptor T cells (CAR-T). These factors include T cell subsets, CAR design, expression promoters and delivery vectors, and CAR-T production process. The comparison between CAR signaling and TCR activation is also discussed. The article provides insights into CAR design for solid tumors, focusing on strategies to improve CAR-T tumor infiltration and survival in the hostile tumor microenvironment.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, Huajun Zhang, Rui Mao, Pierce Brody, Yibing Peng, Aiwu Ruth He, Mercy Kehinde-Ige, Ramses Sadek, Xiangguo Qiu, Huidong Shi, Yukai He
Summary: This study developed new low-affinity monoclonal antibodies and low-avidity CARTs for HCC, demonstrating that low-avidity CARTs can resist exhaustion and maintain functions in solid tumors, generating durable antitumor effects.
Letter
Virology
Yukai He
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Yukai He, Jiying Zhang, Cara Donahue, Louis D. Falo
Article
Immunology
YK He, JY Zhang, ZB Mi, P Robbins, LD Falo
JOURNAL OF IMMUNOLOGY
(2005)